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The Emerging Cross Talk Between Genetics and Epigenetics*Ren-Ke Li, MD, PHD, Jian Guo, MD, PHDSEE PAGE 267C ardiovascular disease is the leading cause ofdeath worldwide, and accumulating evi-dence has demonstrated that mutations in
the gene cluster APOA5/A4/C3/A1 are associated
with hypertriglyceridemia, which may predispose to
atherosclerosis and cardiovascular morbidity and
mortality (1–3). Apolipoprotein A5 (APOA5) is located
proximal to this apolipoprotein gene cluster on chro-
mosome 11q23 (RefSeq: NM_052968). Early animal
studies with transgenic mice expressing a human
APOA5 transgene showed a decrease in plasma tri-
glyceride concentrations, and knockout mice lacking
APOA5 had a 4-fold increase in plasma triglyceride
levels compared with controls (4). APOA5 is a
component of several lipoprotein fractions including
very low density lipoprotein, high-density lipopro-
tein, and chylomicrons, and it is believed that
APOA5 affects lipoprotein metabolism by interacting
with the low-density lipoprotein receptor family of
gene receptors (5). Nonetheless, the precise mecha-
nism by which APOA5 affects triglyceride levels
and how triglyceride levels correlate with coronary
vascular disease remains controversial (6). Current
evidence points to a role for APOA5 in augmenting
the triglyceride lipolytic process by stimulating
lipoprotein lipase (7).
Epigenetic regulation, which has traditionally been
known to include processes such as DNA methylation
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are single-stranded RNA molecules—21 to 23 nucleo-
tides in length—that can bind the 30 UTR region of
messenger RNA transcripts to regulate gene expres-
sion by inhibition of protein synthesis, degradation of
the messenger RNA, or both (8).In this issue of the Journal, Cui et al. (9) present an
innovative study that combines an epidemiological
investigation on a large number of human subjects
and an extensive evaluation of miRNA biology. These
authors sequenced all the exons expressed from the
APOA5/A4/C3/A1 gene cluster in 200 individuals with
extremely high triglyceride levels and 200 matched
control subjects. They also genotyped 20 genetic
markers among 4,991 participants of Chinese Han
ethnicity. Finally, they identiﬁed a unique single
nucleotide polymorphism (SNP) (rs2266788) located
in the 30 UTR region of the APOA5 transcript, which
changes a single nucleotide from a T to a C. This SNP
had a robust correlation with elevated plasma tri-
glyceride levels and vascular lesions. This group also
used approaches used by others to validate miRNA
gene targets (10,11), including in vitro gain- and loss-
of-function approaches that demonstrated that
APOA5 with a T in the 30 UTR position bound miR-
3021, whereas the T to C SNP destroyed the binding
and abolished the repression of APOA5 gene expres-
sion by miRNA-3201. This report is highly novel,
because little is currently known about miRNA-3201
(12). This study may stimulate future intensive in-
vestigations about the function of this SNP (rs2266788)
and its related miRNAs, which will further unveil the
underlying molecular mechanism associated with
genomic variances in the APOA5/A4/C3/A1 gene clus-
ter, the epigenetic functions of regulatory miRNAs,
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FIGURE 1 Cross Talk Between Genomics and Epigenetics
When a single nucleotide polymorphism occurs in the 30 UTR region of a gene’s transcript at a site where microRNAs bind and exert their
regulation on gene expression associated with a particular disease, multiple distinct scenarios are possible. (A) In this example, a T- to-A change
in the 30 UTR of a gene abolishes the binding site of a microRNA (miR-X) that functions to repress this gene, resulting in increased gene
expression and a more pronounced disease phenotype. (B) Yet the same T-to-A change also may create$1 more previously nonexisting binding
site(s) for other microRNAs (miR-Y), resulting in decreased gene expression and alleviating the disease phenotype.
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279and the hypertriglyceridemia associated with this
gene cluster, building a comprehensive foundation for
future therapeutic interventions.
However, we must be aware that the nature of
miRNA biology is extremely complex. Single miRNA
does not simply regulate a single gene in a “one-to-
one” fashion, but instead often functions in a “one-
to-many” or “many-to-one” manner. The regulation
of the w25,000 genes in the human genome by the
w1,000 known miRNAs is highly dynamic and is
surely more complicated than suggested by our cur-
rent understanding. For example, a recent report by
Caussy et al. (13) demonstrated that the T version
(rather than the C version) of the same SNP (rs2266788)
recognized by Cui et al. (9) creates a functional binding
site for a different miRNA, miR-485-5p, which can
modulate APOA5 gene expression. It would be inter-
esting for future investigations to deﬁne the cellular
and tissue source of the newly discoveredmiRNA-3201
and to correlate the spatial and temporal regulation
of miRNA-3201 expression levels and plasma triglyc-
eride levels at different stages of the development ofvascular disease in a tightly controlled animal model.
In addition, future studies will be required to compare
the interrelationship between miRNA-3201, miRNA-
485-5p, and other microRNAs that could potentially
regulate APOA5 gene expression, triglyceride level in
blood, and the occurrence of atherosclerosis. These
studies eventually may translate our knowledge about
this complex gene regulation into a potential novel
therapeutic regimen.
SNPs often are located in noncoding genomic re-
gions and are a major source of diversity among in-
dividuals. SNPs occurring in coding regions can result
in mutant protein products, potentially causing pro-
tein dysfunction and genetic disease. However, SNPs
located in the 30 UTR region (Fig. 1) can illegitimately
generate an artiﬁcial binding site or destroy a pre-
existing miRNA binding site. One such an example
was recently reported: an obesity-associated SNP
(rs8887) that creates an illegitimate miRNA-522
binding site in the 30 UTR of the PLIN4 gene and
promotes down-regulation in adipose tissue (14). A
plethora of similar studies associated with other
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280pathological conditions within the past 2 years has
been reported (15–19). We are witnessing an emerging
cross talk between functional genomics and regula-
tory epigenetics that may permit us to better under-
stand and further investigate the complexity of the
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